An open-label, phase I, dose-escalation and safety study of two intramuscular injections at dose of 2.9 log or 4 log CCID50 of the recombinant HIV I clade B measles vaccine vector in healthy adults.

Date receipt dossier

Company / Sponsor

Institut Pasteur - Paris

Phase

I

Treated organism

Humans

Indication category

Infectious disease

Disease

AIDS

Therapeutic approach

Immunotherapy

Genetic modification

Gag, Pol, Nef genes of HIV

Method of transfer of nucleic acid of interest

Attenuated measles virus Schwarz strain

Administered biological material

Recombinant attenuated measles virus

Route of administration

Intramuscular

Locations in Belgium

UZ Gent

Type of procedure

Contained use only

Current status

Authorized

© Sciensano - Version 1.0 (20260902.1)